Ann Partridge

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial
    Ann H Partridge
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
    J Clin Oncol 31:2692-8. 2013
  2. pmc Model program to improve care for a unique cancer population: young women with breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute and Brigham and Women s Hospital Harvard Medical School, Boston, MA 02215, USA
    J Oncol Pract 8:e105-10. 2012
  3. doi request reprint Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program
    Ann H Partridge
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 119:158-63. 2013
  4. doi request reprint Fertility (male and female) and menopause
    Kathryn J Ruddy
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:3705-11. 2012
  5. pmc The effect of age on delay in diagnosis and stage of breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA
    Oncologist 17:775-82. 2012
  6. ncbi request reprint Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI
    Ann Partridge
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 43:1646-53. 2007
  7. ncbi request reprint Fertility and adjuvant treatment in young women with breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, D1210 Boston, MA 02115, USA
    Breast 16:S175-81. 2007
  8. doi request reprint Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:556-62. 2008
  9. doi request reprint Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study
    Ann Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    J Natl Cancer Inst 100:243-51. 2008
  10. doi request reprint Fertility and menopausal outcomes in young breast cancer survivors
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Breast Cancer 8:65-9. 2008

Detail Information

Publications49

  1. doi request reprint Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial
    Ann H Partridge
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
    J Clin Oncol 31:2692-8. 2013
    ..No prior studies have adequately controlled for human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. We sought to evaluate whether age was a prognostic or predictive factor in the HERA trial...
  2. pmc Model program to improve care for a unique cancer population: young women with breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute and Brigham and Women s Hospital Harvard Medical School, Boston, MA 02215, USA
    J Oncol Pract 8:e105-10. 2012
    ..We believe this work will not only improve care for young women with breast cancer, but also may serve as a paradigm to overcome barriers to delivering optimal care for unique groups of patients in other settings...
  3. doi request reprint Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program
    Ann H Partridge
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 119:158-63. 2013
    ..Data were used to create and share treatment plans/summaries (TPSs) at the point of care...
  4. doi request reprint Fertility (male and female) and menopause
    Kathryn J Ruddy
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:3705-11. 2012
    ..For cancer survivors who experience menopausal symptoms, lifestyle changes may be beneficial, and hormonal and nonhormonal pharmacologic agents are well proven to reduce symptom burden...
  5. pmc The effect of age on delay in diagnosis and stage of breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA
    Oncologist 17:775-82. 2012
    ..We sought to examine the relationship among young age (≤40 years), the likelihood of a delay in diagnosis, and stage...
  6. ncbi request reprint Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI
    Ann Partridge
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 43:1646-53. 2007
    ..The likelihood of premature menopause has not been thoroughly explored in women who remain premenopausal after adjuvant chemotherapy for breast cancer...
  7. ncbi request reprint Fertility and adjuvant treatment in young women with breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, D1210 Boston, MA 02115, USA
    Breast 16:S175-81. 2007
    ..Ongoing and future prospective studies evaluating fertility and pregnancy issues for young breast cancer survivors are warranted for this vulnerable population facing this difficult issue...
  8. doi request reprint Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:556-62. 2008
    ..Previous research evaluating adherence to tamoxifen therapy among women with early-stage breast cancer has revealed adherence estimates ranging from 25% to 96%. No previous studies have focused on adherence to adjuvant aromatase inhibitors...
  9. doi request reprint Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study
    Ann Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    J Natl Cancer Inst 100:243-51. 2008
    ..Preliminary studies have suggested that women with DCIS may overestimate their risk of disease recurrence. Few data exist regarding psychosocial outcomes for women with DCIS...
  10. doi request reprint Fertility and menopausal outcomes in young breast cancer survivors
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Breast Cancer 8:65-9. 2008
    ..We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival Coalition, an international advocacy group for young women with breast cancer...
  11. doi request reprint The impact of sharing results of a randomized breast cancer clinical trial with study participants
    Ann H Partridge
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 115:123-9. 2009
    ..We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and the impact of learning results...
  12. doi request reprint Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ
    Ann Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 8:275-80. 2008
    ..We sought in a longitudinal cohort study of women with DCIS to assess the attitudes and management approaches toward DCIS among physicians who provide care to women...
  13. doi request reprint Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Fertil Steril 94:638-44. 2010
    ..To compare markers of ovarian reserve between women exposed to cytotoxic chemotherapy for early stage breast cancer and matched controls...
  14. ncbi request reprint Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants
    Ann H Partridge
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 96:629-32. 2004
    ..Future studies should consider sharing trial results with patients and evaluating the process and its effect on both patients and clinicians...
  15. pmc Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104
    Ann H Partridge
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:2418-22. 2010
    ..Patient adherence is critical in evaluating the effectiveness of an oral therapy. We sought to measure adherence among women randomly assigned to capecitabine in a preplanned substudy of a multicenter clinical trial...
  16. ncbi request reprint Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Ann H Partridge
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1210, Boston, MA 02215, USA
    J Clin Oncol 21:602-6. 2003
    ..We sought to estimate adherence and predictors of nonadherence in women starting tamoxifen as adjuvant breast cancer therapy...
  17. ncbi request reprint Web-based survey of fertility issues in young women with breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:4174-83. 2004
    ..Young women with breast cancer often seek advice about whether treatment will affect their fertility. We sought to gain a better understanding of women's attitudes about fertility and how these concerns affect decision making...
  18. ncbi request reprint Offering participants results of a clinical trial: sharing results of a negative study
    Ann H Partridge
    Department of Medical and Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 365:963-4. 2005
    ..006). Most participants reported positive feelings about being offered results and about clinical trials in general. These preliminary findings from sharing clinical trial results are encouraging...
  19. pmc Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907
    Alice B Kornblith
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 29:1022-8. 2011
    ..The quality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better QoL than standard chemotherapy...
  20. doi request reprint Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ
    Jennifer A Ligibel
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann Surg Oncol 16:106-12. 2009
    ..Women who underwent mastectomy, as well as women who were more anxious, were more likely to decrease their level of physical activity. Women with DCIS might benefit from targeted interventions to increase physical activity...
  21. doi request reprint Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer
    Jennifer A Ligibel
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    J Womens Health (Larchmt) 19:1553-9. 2010
    ..Studies have suggested that decreases in physical activity during treatment may contribute to weight gain in breast cancer patients...
  22. doi request reprint Medication errors involving oral chemotherapy
    Saul N Weingart
    Center for Patient Safety, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 116:2455-64. 2010
    ..Given the expanding use of oral chemotherapies, the authors set out to examine errors in the prescribing, dispensing, administration, and monitoring of these drugs...
  23. ncbi request reprint An approach to measuring the quality of breast cancer decisions
    Karen Sepucha
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Patient Educ Couns 65:261-9. 2007
    ....
  24. doi request reprint Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ
    Sharon L Bober
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Sex Med 10:370-7. 2013
    ..This is of particular importance because many of the parallel treatment modalities also used to treat invasive breast cancer, e.g., surgery and hormonal therapy, have been shown to have a detrimental effect on psychosexual function...
  25. doi request reprint The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer
    Mary E Abusief
    Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 116:791-8. 2010
    ..Little information is available regarding the effects of new adjuvant treatment regimens on menstrual functioning in premenopausal women with early breast cancer...
  26. ncbi request reprint Long-term complications of adjuvant chemotherapy for early stage breast cancer
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Breast Dis 21:55-64. 2004
    ..Interventions to ameliorate long-term complications are also addressed...
  27. ncbi request reprint Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  28. doi request reprint Patient adherence and persistence with oral anticancer treatment
    Kathryn Ruddy
    Department of Breast Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    CA Cancer J Clin 59:56-66. 2009
    ..Studies that included educational, behavioral, and multidimensional interventions to improve adherence were also described...
  29. doi request reprint Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors
    Jennifer A Ligibel
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Channing Laboratory, Boston, MA, USA
    J Clin Oncol 26:907-12. 2008
    ..We sought to analyze whether exercise lowered insulin concentrations in breast cancer survivors...
  30. pmc Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery
    Karen R Sepucha
    General Medicine Division, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    BMC Med Inform Decis Mak 12:51. 2012
    ..The purpose of this paper is to examine the acceptability, feasibility, reliability and validity of a new decision quality instrument that assesses the extent to which patients are informed and receive treatments that match their goals...
  31. pmc Coping and psychological distress in young adults with advanced cancer
    Kelly M Trevino
    Department of Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, MA, USA
    J Support Oncol 10:124-30. 2012
    ..Little is known about how young adults (YAs) cope with cancer or about the relationship between coping and psychological distress in YAs with advanced cancer...
  32. doi request reprint Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial
    Hadine Joffe
    Perinatal and Reproductive Psychiatry Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Menopause 17:908-16. 2010
    ..Alternative strategies are needed. We hypothesized that augmentation of SSRI/SNRI therapy with hypnotic agents would optimize hot flash therapy by improving sleep and quality of life...
  33. doi request reprint Doctor-patient communication about advance directives in metastatic breast cancer
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, USA
    J Palliat Med 12:547-53. 2009
    ..This study examined whether or not patients with metastatic breast cancer had advance directives, and if so, with whom they discussed written plans for end-of-life decisions...
  34. ncbi request reprint Pregnancy and breast cancer: epidemiology, treatment, and safety issues
    Ann Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Oncology (Williston Park) 19:693-7; discussion 697-700. 2005
    ....
  35. ncbi request reprint Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors: a comparison to age- and gravidity-matched controls
    Kathryn J Ruddy
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Menopause 18:105-8. 2011
    ..However, there has been little research to date comparing young survivors’ concerns and symptoms with those of young women of the same age and gravidity in the general population...
  36. ncbi request reprint Treatment of breast cancer during pregnancy
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Pharmacother 3:423-8. 2002
    ..Treatment decisions need to be tailored carefully to the individual, respecting both her clinical circumstances and her personal preferences...
  37. doi request reprint Is there a role for decision aids in advanced breast cancer?
    Karen R Sepucha
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Med Decis Making 29:475-82. 2009
    ..A diagnosis of metastatic breast cancer (BC) forces patients and providers to make difficult treatment decisions...
  38. ncbi request reprint Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8340-7. 2005
    ..The role of long-acting hematopoietic growth factors in facilitating every-2-week chemotherapy and minimizing hematologic toxicity has not been established...
  39. doi request reprint Fertility preservation: a vital survivorship issue for young women with breast cancer
    Ann H Partridge
    J Clin Oncol 26:2612-3. 2008
  40. ncbi request reprint Breast cancer in young women: a new color or a different shade of pink?
    Jeffrey Peppercorn
    J Clin Oncol 26:3303-5. 2008
  41. pmc Oral chemotherapy safety practices at US cancer centres: questionnaire survey
    Saul N Weingart
    Center for Patient Safety, Dana Farber Cancer Institute, Boston, MA 02115, USA
    BMJ 334:407. 2007
    ..To characterise current safety practices for the use of oral chemotherapy...
  42. ncbi request reprint Breast cancer risk communication: challenges and future research directions: workshop report (United States)
    Larissa Nekhlyudov
    Department of Ambulatory Care and Prevention, Harvard Medical School Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Cancer Causes Control 14:235-9. 2003
    ..This report describes the proceedings of the conference...
  43. ncbi request reprint Adherence to therapy with oral antineoplastic agents
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 94:652-61. 2002
    ..Assessment of adherence among individuals with cancer and implementation of interventions in situations of poor adherence should improve clinical outcomes...
  44. ncbi request reprint Fertility after breast cancer: questions abound
    Ann H Partridge
    J Clin Oncol 23:4259-61. 2005
  45. ncbi request reprint Young women's preferences about adjuvant endocrine therapy for breast cancer
    Ann H Partridge
    Lancet Oncol 6:542-4. 2005
  46. doi request reprint High performance teamwork training and systems redesign in outpatient oncology
    Craig A Bunnell
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    BMJ Qual Saf 22:405-13. 2013
    ..To address this risk, we developed and piloted a team training initiative in the breast cancer programme at a comprehensive cancer centre...
  47. ncbi request reprint Follow-up care of breast cancer survivors
    Ann H Partridge
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 30:817-25. 2003
    ..Clinicians can also provide guidance and counseling as well as psychosocial support to patients regarding medical and psychosocial decisions that may be affected by their personal history of breast cancer...
  48. ncbi request reprint American Society of Clinical Oncology recommendations on fertility preservation in cancer patients
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:2917-31. 2006
    ..To develop guidance to practicing oncologists about available fertility preservation methods and related issues in people treated for cancer...
  49. ncbi request reprint Informing clinical trial participants about study results
    Ann H Partridge
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    JAMA 288:363-5. 2002